AMRX - FDA accepts Amneal's Bevacizumab BLA for review shares rise

Amneal Pharmaceuticals (AMRX) announces that the U.S. FDA has accepted for review the Biologics License Application ((BLA)) for Bevacizumab for the treatment of metastatic colorectal cancer.Shares up more than 8% premarket.The health regulator has also set a standard review goal date in the second quarter of 2022 .Bevacizumab is the biosimilar version of Avastin and when approved will be marketed under the proprietary name Alymsys.The FDA had accepted a New Drug Application from Amneal for a dihydroergotamine ("DHE") prefilled syringe autoinjector for migraines and cluster headaches, last week.

For further details see:

FDA accepts Amneal's Bevacizumab BLA for review, shares rise